AA
AZN icon

AlphaCentric Advisors’s AstraZeneca AZN Stock Holding History

AlphaCentric Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.16M Buy
11,394
+162
+1% +$30.5K 1.83% 4
2026
Q1 		$2.22M Buy
11,232
+610
+6% +$118K 2.21% 4
2025
Q4 		$1.95M Buy
+10,622
New +$1.86M 1.95% 6
2024
Q4 		$2.08M Buy
+15,843
New +$2.22M 2.07% 8

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AlphaCentric Advisors's AZN Position: Q2 2026 in Review

AlphaCentric Advisors increased its AstraZeneca (AZN) stake by 1.4% in Q2 2026, buying an estimated $30.5K and bringing the position to 11,394 shares worth $2.16M. The position accounts for 1.83% of the portfolio, ranked #4.

AlphaCentric Advisors first reported a position in AZN in Q4 2024 and has held it in 4 quarters since. The position peaked at $2.22M in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • AlphaCentric Advisors held 11,394 shares of AstraZeneca worth $2.16M as of Q2 2026.
  • AlphaCentric Advisors bought 162 AstraZeneca shares in Q2 2026, an estimated $30.5K.
  • AstraZeneca made up 1.83% of AlphaCentric Advisors's portfolio in Q2 2026, its #4 holding.
  • AlphaCentric Advisors first reported a position in AstraZeneca in Q4 2024 and has held it in 4 quarters since.
  • AlphaCentric Advisors's AstraZeneca position peaked at $2.22M in Q1 2026.
  • 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.